Recursion Pharmaceuticals (RXRX) Cost of Revenue (2022 - 2026)

Recursion Pharmaceuticals (RXRX) has 5 years of Cost of Revenue data on file, last reported at $12.5 million in Q1 2026.

• Quarterly Cost of Revenue fell 42.78% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.6 million (up 10.22% YoY) and the FY2025 annual result came in at $71.0 million, up 56.84% from the prior year.
• Cost of Revenue declined to $12.5 million in Q1 2026, from $14.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21.8 million in Q1 2025 to a low of $7.8 million in Q1 2022.
• A 5-year average of $12.9 million and a median of $12.4 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2025 — Cost of Revenue jumped 119.17% — and 2026, when it slumped 42.78%.
• Tracing RXRX's Cost of Revenue over 5 years: stood at $10.8 million in 2022, then fell by 8.85% to $9.9 million in 2023, then climbed by 29.48% to $12.8 million in 2024, then increased by 11.58% to $14.3 million in 2025, then fell by 12.5% to $12.5 million in 2026.
• The last three Cost of Revenue figures came in at $12.5 million (Q1 2026), $14.3 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.